| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Wessam E Sharaf-Eldin | Q87181517 |
| Marwa Mahmoud | Q87181520 | ||
| Nourhan Abu-Shahba | Q64503968 | ||
| P2093 | author name string | Nagwa El-Badri | |
| P2860 | cites work | Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells | Q79208808 |
| Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells | Q79361043 | ||
| Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells | Q80057941 | ||
| Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells | Q80216977 | ||
| Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells | Q80415050 | ||
| Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway | Q80637499 | ||
| Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways | Q80763818 | ||
| Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice | Q81386359 | ||
| Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat | Q81387247 | ||
| Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway | Q81406086 | ||
| Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint | Q81756339 | ||
| Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes | Q84105212 | ||
| Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-α stimulated gene/protein 6 | Q84753164 | ||
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Stem cell therapy to cure type 1 diabetes: from hype to hope | Q26823294 | ||
| Skeletal stem cells | Q26823973 | ||
| Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts | Q26828486 | ||
| The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis | Q26864614 | ||
| A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods | Q26998969 | ||
| Immunobiology of mesenchymal stem cells | Q27004487 | ||
| Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement | Q27861120 | ||
| Matrix-embedded cells control osteoclast formation | Q28247746 | ||
| Evidence for osteocyte regulation of bone homeostasis through RANKL expression | Q28247757 | ||
| Human mesenchymal stem cells modulate allogeneic immune cell responses | Q28288692 | ||
| Regulation of osteoclast differentiation | Q28593319 | ||
| Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study | Q29617267 | ||
| Mesenchymal stem cells reside in virtually all post-natal organs and tissues | Q29617740 | ||
| Pluripotency of mesenchymal stem cells derived from adult marrow | Q29617959 | ||
| Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells | Q29618766 | ||
| Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli | Q29618769 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 | Q29620590 | ||
| Human mesenchymal stem cells modulate B-cell functions | Q29620705 | ||
| Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus | Q33269870 | ||
| Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner | Q33438830 | ||
| Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures | Q33636797 | ||
| The interaction between mesenchymal stem cells and steroids during inflammation | Q33695051 | ||
| Placental mesenchymal stem cells of fetal and maternal origins demonstrate different therapeutic potentials | Q33746577 | ||
| Concerted action of Smad and CREB-binding protein regulates bone morphogenetic protein-2-stimulated osteoblastic colony-stimulating factor-1 expression | Q40278602 | ||
| Treatment of Myoblastic C2C12 Cells with BMP-2 Stimulates Vitamin D-induced Formation of Osteoclasts | Q40631790 | ||
| IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro | Q40814402 | ||
| The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated | Q40838648 | ||
| Human mesenchymal stem cells promote human osteoclast differentiation from CD34+ bone marrow hematopoietic progenitors | Q40937743 | ||
| Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells | Q41004339 | ||
| The role of osteoblast density and endogenous interleukin-6 production in osteoclast formation from the hemopoietic stem cell line FDCP-MIX C2GM in coculture with primary osteoblasts | Q41030938 | ||
| Heat-treated osteoblastic cell (ROS17/2.8)-conditioned medium induces the formation of osteoclast-like cells | Q41515614 | ||
| Cloning of an osteoblastic cell line involved in the formation of osteoclast-like cells | Q41713781 | ||
| Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far? | Q42103653 | ||
| Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism | Q42828277 | ||
| Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series. | Q42862373 | ||
| Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases | Q43011355 | ||
| Accelerated alveolar bone loss in mice lacking interleukin-10: late onset | Q43520837 | ||
| Transforming growth factor-beta induces osteoclast ruffling and chemotaxis: potential role in osteoclast recruitment. | Q43671898 | ||
| Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy | Q43823986 | ||
| PTH differentially regulates expression of RANKL and OPG. | Q43832667 | ||
| Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. | Q45959326 | ||
| Inhibiting and stimulating effects of TGF-beta 1 on osteoclastic bone resorption in fetal mouse bone organ cultures | Q46192845 | ||
| Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. | Q46670167 | ||
| Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production | Q46763990 | ||
| Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture | Q47409578 | ||
| Tumor necrosis factor-alpha alters the modulatory effects of mesenchymal stem cells on osteoclast formation and function | Q47991417 | ||
| Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells | Q33803260 | ||
| The cell biology of osteoclast function. | Q33819720 | ||
| Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. | Q34007524 | ||
| Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone | Q34066339 | ||
| Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages | Q34168340 | ||
| CD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cells | Q34171231 | ||
| Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy | Q34259085 | ||
| Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond | Q34366449 | ||
| Physiological functions of osteoblast lineage and T cell-derived RANKL in bone homeostasis | Q34369482 | ||
| Mesenchymal stem cells markedly suppress inflammatory bone destruction in rats with adjuvant-induced arthritis | Q34396114 | ||
| Interleukin-17 enhances immunosuppression by mesenchymal stem cells | Q34413472 | ||
| Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression | Q34495205 | ||
| Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies | Q34744250 | ||
| CD200R/CD200 inhibits osteoclastogenesis: new mechanism of osteoclast control by mesenchymal stem cells in human | Q34938505 | ||
| Stem cells derived from amniotic fluid: new potentials in regenerative medicine | Q34961663 | ||
| The genetic basis for skeletal diseases | Q35128232 | ||
| Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages | Q35215695 | ||
| Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors | Q35617591 | ||
| IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology | Q35640443 | ||
| Transplantation of mesenchymal stem cells ameliorates secondary osteoporosis through interleukin-17-impaired functions of recipient bone marrow mesenchymal stem cells in MRL/lpr mice | Q35761240 | ||
| The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues | Q35838186 | ||
| Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury | Q35841729 | ||
| RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis | Q35885679 | ||
| Modulation of osteoclast differentiation | Q35957509 | ||
| The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling | Q35961678 | ||
| Vascular endothelial growth factor is a key mediator in the development of T cell priming and its polarization to type 1 and type 17 T helper cells in the airways | Q36065935 | ||
| Transforming growth factor-beta1 to the bone | Q36131663 | ||
| Mesenchymal stem cells: a double-edged sword in regulating immune responses | Q36174037 | ||
| Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss | Q36216058 | ||
| TNF-alpha and pathologic bone resorption | Q36291539 | ||
| Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). | Q36372136 | ||
| Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors | Q36375584 | ||
| TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
| Molecular mechanism of the life and death of the osteoclast | Q36532524 | ||
| TGF-beta1 on osteoimmunology and the bone component cells | Q36591727 | ||
| Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts | Q36681378 | ||
| Functions of RANKL/RANK/OPG in bone modeling and remodeling | Q36700779 | ||
| Dissociation between bone resorption and bone formation in osteopenic transgenic mice | Q36800774 | ||
| Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. | Q36860987 | ||
| The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell | Q36979047 | ||
| Concise review: mesenchymal stem cells and translational medicine: emerging issues. | Q37056276 | ||
| Cross-talk between T cells and osteoclasts in bone resorption | Q37056309 | ||
| Commitment to the osteoblast lineage is not required for RANKL gene expression | Q37176364 | ||
| IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression | Q37342418 | ||
| Mesenchymal stem cells suppress B-cell terminal differentiation. | Q37355322 | ||
| Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors | Q37438518 | ||
| Identification of specific cell-surface markers of adipose-derived stem cells from subcutaneous and visceral fat depots | Q37581652 | ||
| Osteoclasts have multiple roles in bone in addition to bone resorption | Q37626090 | ||
| Mechanisms involved in the therapeutic properties of mesenchymal stem cells | Q37635499 | ||
| Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair | Q37724579 | ||
| Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications | Q37760962 | ||
| Mesenchymal stromal cell 'licensing': a multistep process | Q37880625 | ||
| Immunosuppressive properties of mesenchymal stem cells | Q37926524 | ||
| The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption | Q37929460 | ||
| Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements | Q37945318 | ||
| Role of mesenchymal stem cell therapy in Crohn's disease | Q37995012 | ||
| Inflammation in aging: cause, effect, or both? | Q38022324 | ||
| Immunological goings-on in visceral adipose tissue | Q38112933 | ||
| Clinical applications of mesenchymal stem cells | Q38122364 | ||
| Mesenchymal stromal cells: sensors and switchers of inflammation | Q38149359 | ||
| Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications | Q38261365 | ||
| Rationale for the potential use of mesenchymal stromal cells in liver transplantation | Q38282065 | ||
| Mesenchymal stem cells: a friend or foe in immune-mediated diseases. | Q38319943 | ||
| Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis | Q39365959 | ||
| Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production. | Q39584342 | ||
| Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of CXCR4 and cbfa-1 co-expressing mesenchymal stem cells | Q39900835 | ||
| Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 | ||
| Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. | Q51002334 | ||
| Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. | Q51005281 | ||
| Temporal and spatial expression of osteoprotegerin and receptor activator of nuclear factor -kappaB ligand during mandibular distraction in rats. | Q51021098 | ||
| Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. | Q51134056 | ||
| Osteoclastogenesis on tissue-engineered bone. | Q51703633 | ||
| Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. | Q52001009 | ||
| Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. | Q52172979 | ||
| Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. | Q53753309 | ||
| Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. | Q54011232 | ||
| A role for TGFbeta(1) in osteoclast differentiation and survival. | Q54048285 | ||
| A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells | Q56765649 | ||
| Vitamin D Action and Regulation of Bone Remodeling: Suppression of Osteoclastogenesis by the Mature Osteoblast | Q57533550 | ||
| RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β | Q57675150 | ||
| Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells | Q61645531 | ||
| Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide | Q61645540 | ||
| Mesenchymal Stem Cells Require a Sufficient, Ongoing Immune Response to Exert Their Immunosuppressive Function | Q61878551 | ||
| The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells | Q69541163 | ||
| Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro | Q69738552 | ||
| Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor | Q73490934 | ||
| Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture | Q73853199 | ||
| Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells | Q74027807 | ||
| A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro | Q77342999 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mesenchymal stem cell | Q1922379 |
| P304 | page(s) | 1908365 | |
| P577 | publication date | 2015-12-28 | |
| P1433 | published in | Stem Cells International | Q26842114 |
| P1476 | title | The Modulatory Effects of Mesenchymal Stem Cells on Osteoclastogenesis | |
| P478 | volume | 2016 |
| Q92001233 | Bone Defect Repair Using a Bone Substitute Supported by Mesenchymal Stem Cells Derived from the Umbilical Cord |
| Q91712822 | CR6-interacting factor-1 contributes to osteoclastogenesis by inducing receptor activator of nuclear factor κB ligand after radiation |
| Q93061354 | Changes in gene expression in human skeletal stem cells transduced with constitutively active Gsα correlates with hallmark histopathological changes seen in fibrous dysplastic bone |
| Q91960184 | Hydroxylapatite-collagen hybrid scaffold induces human adipose-derived mesenchymal stem cells to osteogenic differentiation in vitro and bone regrowth in patients |
| Q90411548 | Oral Mesenchymal Stem/Progenitor Cells: The Immunomodulatory Masters |
| Q46183672 | Pro-inflammatory M1 macrophages promote Osteogenesis by mesenchymal stem cells via the COX-2-prostaglandin E2 pathway. |
| Q33695185 | Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate. |
| Q100490792 | Tankyrase inhibitor XAV-939 enhances osteoblastogenesis and mineralization of human skeletal (mesenchymal) stem cells |
| Q47167957 | The Effect of RANKL/OPG Balance on Reducing Implant Complications |
Search more.